Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 5 of 73 TABLE OF CONTENTS  
1. PROTOCOL SUMMARY  ..........................................................................................10  
1.1. Synopsis ......................................................................................................................10  
1.2. Study Schema .............................................................................................................15  
1.3. Schedule of Visits and Assessments  ...........................................................................16  
2. ABBREVIATIONS  ....................................................................................................19  
3. BACKGROUND AND RATIONALE  .......................................................................21  
3.1. Introduction .................................................................................................................21  
3.2. Preclinical Studies  ......................................................................................................22  
3.2.1.  Toxicity Summary  ......................................................................................................22  
3.3. Clinical Studies  ...........................................................................................................23  
3.3.1.  Topical Roflumilast Cream .........................................................................................23  
3.3.1.1.  Psoriasis Phase 2a  .......................................................................................................23  
3.3.1.2.  Psoriasis Phase 2b  .......................................................................................................24  
3.3.1.3.  Atopic Dermatitis Phase 1  ..........................................................................................28  
3.3.1.4.  Atopic Dermatitis Phase 2  ..........................................................................................28  
3.3.2.  Oral Roflumilast Tablet  ..............................................................................................29  
3.4. Rationale for Development .........................................................................................29  
3.4.1.   
3.4.2.   
4. STUDY ENDPOINTS AND OBJECTIVES  ..............................................................31  
4.1. Study Objective ..........................................................................................................31  
4.2. Study Endpoints ..........................................................................................................31  
4.2.1.  Prima ry Endpoints ......................................................................................................31  
4.2.2.  Secondary Endpoints ..................................................................................................31  
5. INVESTIGATIONAL PLAN  .....................................................................................32  
5.1. Overa ll Study Design and Plan ...................................................................................32  
5.2. Number of Sites and Subjects .....................................................................................32  
5.3. Subject Participation  ...................................................................................................33  
5.3.1.  Numbering of Subjects  ...............................................................................................33  
5.4. Selection of Study Population ....................................................................................33  
5.4.1.  Inclusion Criteria  ........................................................................................................33  

Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 6 of 73 5.4.2.  Exclusion Criteria  .......................................................................................................34  
5.4.3.  Removal of Subjects from Investigational Product ....................................................36  
5.4.4.  Removal of Subjects from the Study  ..........................................................................36  
5.5. Study Restrictions .......................................................................................................37  
5.5.1.  Prohibitions and Concomitant Therapy ......................................................................37  
5.6. Treatment  ....................................................................................................................38  
5.6.1.  IP Supplies, Packaging and Labeling .........................................................................38  
5.6.2.  Blinding ......................................................................................................................38  
5.6.3.  Treatment Administration  ...........................................................................................38  
5.6.4.  Treatment Compliance  ................................................................................................39  
6. STUDY PROCEDURES  ............................................................................................40  
6.1. Safety Assessments  .....................................................................................................40  
6.1.1.  Physical Examination  .................................................................................................41  
6.1.2.  Vital Signs, Height and Weight  ..................................................................................41  
6.1.3.  Laboratory Tests  .........................................................................................................41  
6.1.4.  Patient Health Questionnaire depression scale (PHQ -8) ............................................42  
6.1.5.  Patient Health Questionnaire depression scale (Modified PHQ -A) ...........................42  
6.1.6.  Children’s Depression Inventory 2 .............................................................................43  
6.1.7.  Columbia- Suicide Severity Rating Scale (C -SSRS)  ...................................................43  
6.1.8.  Local Tolerability Assessments  ..................................................................................44  
6.1.9.  Pigmentation Assessment  ...........................................................................................45  
6.1.10.  Adverse Events ...........................................................................................................45  
6.1.11.  Phone Visits ................................................................................................................45  
6.1.12.  Pharmacokinetic Assessment  ......................................................................................45  
6.1.13.  Malassezia T esting  ......................................................................................................46  
6.2. Efficacy Evaluations  ...................................................................................................46  
6.2.1.  Investigator Global Assessment (IGA)  .......................................................................46  
6.2.2.  Overall Assessment of Erythema  ................................................................................46  
6.2.3.  Overall Assessment of Scaling  ...................................................................................47  
6.2.4.  Body Surface Area (BSA)  ..........................................................................................47  
6.2.5.  Worst Itch Numerical Rating Scale (WI- NRS)  ..........................................................47  
6.2.6.  Scalpdex  ......................................................................................................................48  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 7 of 73 6.2.7.  Dermal Imaging  ..........................................................................................................48  
6.3. Final S tudy Visit  .........................................................................................................48  
6.4. Early Termination Visit  ..............................................................................................48  
6.5. Unscheduled Visit .......................................................................................................48  
6.6. Adverse Events ...........................................................................................................49  
6.6.1.  Adverse Event Definition  ...........................................................................................49  
6.6.2.  Serious Adverse Event  ................................................................................................49  
6.6.3.  Suspected Unexpected Serious Adverse Reaction (SUSAR)  .....................................51  
6.6.4.  Safety Review  .............................................................................................................51  
6.6.5.  Adverse Event Reporting ............................................................................................51  
6.7. Reporting Pregnancy ..................................................................................................52  
6.8. Treatment Stopping Rules ..........................................................................................52  
7. DATA ANALYSIS  ....................................................................................................54  
7.1. Statistical Methods  ......................................................................................................54  
7.1.1.  Baseline Definition  .....................................................................................................54  
7.1.2.  Determination of Sample Size  ....................................................................................54  
7.1.3.  Subjects to Analyze  ....................................................................................................55  
7.1.4.  Interim Analysis  ..........................................................................................................55  
7.1.5.  Background and Demographic Characteristics ..........................................................55  
7.1.6.  Study Disposition........................................................................................................55  
7.1.7.  Protocol Deviations and Eligibility Deviations ..........................................................55  
7.1.8.  Investigational Product Compliance  ...........................................................................55  
7.2. Safety Evaluation ........................................................................................................55  
7.2.1.  Adverse Events ...........................................................................................................55  
7.2.2.  Local Tolerance Assessments  .....................................................................................56  
7.2.3.  Medical History and Physical Examinations ..............................................................56  
7.2.4.  PHQ-8 and Modified PHQ-A .....................................................................................56  
7.2.5.  C-SSRS  .......................................................................................................................56  
7.2.6.  Clinical Laboratory Results and Vital Signs/Weight Measurements  .........................56  
7.2.7.  Prior and Concomitant Medications ...........................................................................57  
7.3. Patient Reported Outcomes Analyses .........................................................................57  
7.3.1.  WI-NRS  ......................................................................................................................57  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 8 of 73 7.3.2.  Scalpdex  ......................................................................................................................57  
7.4. Efficacy Endpoints ......................................................................................................57  
7.4.1.  Achievement of IGA ‘Completely Clear’ or ‘Almost Clear’  .....................................57  
7.4.2.  Achievement of IGA ‘Completely Clear’ or ‘Almost Clear’ plus a 2 -grade 
Improvement from Baseline  .......................................................................................57  
7.4.3.  Achievement of a 2 -grade improvement in IGA from Baseline  .................................57  
7.4.4.  Duration of IGA Success ............................................................................................57  
7.4.5.  Treatment -free Interval  ...............................................................................................58  
7.4.6.  Pharmacokinetic Analysis  ..........................................................................................58  
8. STUDY ADMINISTRATION  ...................................................................................58  
8.1. Ethics  ..........................................................................................................................58  
8.1.1.  Ethics Review Board  ..................................................................................................58  
8.1.2.  Ethical Conduct of the Study ......................................................................................58  
8.1.3.  Subject Information and Consent  ...............................................................................58  
8.2. Study Completion and Termination ............................................................................59  
8.2.1.  Study Completion .......................................................................................................59  
8.2.2.  Study Termination ......................................................................................................59  
8.3. Study Monitoring ........................................................................................................59  
8.4. Data Quality Assurance  ..............................................................................................60  
8.5. Data Handling and Record Keeping ...........................................................................60  
8.6. Protocol Amendments and Deviations .......................................................................60  
8.7. Confidentiality and Privacy ........................................................................................61  
8.8. Conflict of Interest  ......................................................................................................61  
8.9. Report Format  .............................................................................................................61  
8.10.  Publication Policy  .......................................................................................................62  
9. REFERENCES ...........................................................................................................63  
10. APPENDICES ............................................................................................................64  
APPENDIX  1. PATIEN T HEALTH QUESTIONNAIRE DEPRESSION SCALE 
(PHQ-8) ..............................................................................................................64  
APPENDIX  2. PATIENT HEALTH QUESTIONNAIRE DEPRESSION SCALE 
(MODIFIED PHQ- A) .........................................................................................65  
APPENDIX  3. COLUMBIA- SUICIDE SEVERITY RATING SCALE (C- SSRS) 
BASELINE/SCREENING VERSION  ...............................................................66  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 10 of 73  1. PROTOCOL SUMMARY  
1.1. Synopsis  
Protocol Title:  A Phase 2, Multicenter , Open -Label Study of the Long-Term Safety 
of ARQ-154 Foam 0.3% in Subjects with Seborrheic Dermatitis  
Investigational Product: ARQ-154 investigational product will be supplied a s a 0.3% foam  
IND: 142047  
Clinical Indication:  Seborrheic dermatitis  
Study Design : ARQ-154-214 is an open-label, single -arm, long -term safety study of 
ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving 
up to 20% total BSA.  
Cohort 1 eligible subjects will enroll into the long-term safety study 
on the same day as the final visit for a previous  ARQ- 154 study. 
Cohort 1 Group 1 will be subjects who rolled  over from the previous 
ARQ-154-203 study. Group 2 will be subjects who rolled over from 
the previous ARQ -154-116 study. Cohort 2 eligible subjects will 
enroll on Day 1 of thi s study.  Investigational product  will be applied 
by the eligible subjects topically QD for up to 52 weeks at home. 
Periodic clinic visits will include assessments for clinical safety, 
application site reactions evaluated in the clinic using the method of 
Berger and Bowman, and disease improvement or progression.  
Final analysis will be performed when subjects in Cohort 1 Group 1 
and Cohort 2 (approximately 400 subjects) finish up to 52 weeks  of 
treatment.    
Subjects in Cohort 1 Group 2 (approximately 10 subjects) will only 
be summarized  in the listings and will be updated once all Group 2 
subjects finish up to 52 weeks of treatment. A CSR addendum will be 
provided based on the update d Cohort  1 Group 2 listing.   
Study Objectives:  To assess long -term safety in  a multicenter, open -label,  single -arm  
52-week study in  subjects with seborrheic dermatitis treated with  
ARQ-154 foam  0.3% . 
Study Sites: Up to a pproximately 40 sites in North America  
Study Population:  Up to a pproximately 410 subjects total will be enrolled across 
Cohorts 1 and 2.  
For Cohort 1, subjects will be male and female adolescents (9 -17 y/o) 
and adults ( >18 y/o)  who have completed the treatment period in  a 
prior  ARQ-154 study  and immediately  enroll in t his safety study.  
Cohort 1 Group 1 subjects will be the ones who rolled over from 
ARQ-154-203. Cohort 1 Group 2 subjects will be the ones who 
rolled over from ARQ -154-116. For Cohort 2, subjects will be male 
and female adolescents (12 – 17 y/o) and adults  (>18 y/o) subjects 
who may or may not have  participated in a prior ARQ-154 study , 
i.e. either de novo subjects who did not participate in ARQ -154-203 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 11 of 73  or subjects who completed a ARQ -154 study prior to initiation of the 
current ARQ- 154-214 study .  
Inclusion Criteria : 
All Subjects  1. Participants legally competent to sign and give informed consent 
or (for adolescents) assent. 
2. Males and females ages 9 years and older (inclusive) at the time 
of consent . 
3. Females of childbearing potential (FOCBP) must have a 
negative urine pregnancy test at all study visits. In addition, 
sexually active FOCBP must agree to use at least one form of an 
acceptable effective contraception throughout the trial.  
Acceptable effective forms of contraception may include: 
oral/implant/injectable/ transdermal contraceptives, intrauterine 
device, or partner’s vasectomy.  If barrier methods are used 
(e.g., condom with spermicide, diaphragm with spermicide), 
then 2 forms of contra ception  are required. The use of abstinence 
as a contraceptive measure is acceptable as long as this is a 
consistent part of a lifestyle choice and a backup method has 
been identified if the subject becomes sexually active.  
4. Females of non -childbearing potential m ust be either 
premenarchal or post-menopausal women with spontaneous 
amenorrhea for at least 12 months or have undergone surgical 
sterilization (permanent sterilization methods include 
hysterectomy, bilateral oophorectomy, hysteroscopic 
sterilization, bilateral tubal ligation or bilateral salpingectomy).  
Inclusion Criteria : 
Cohort 1 Only 5. Subjects with seborrheic dermatitis who met eligibility criteria 
for a prior ARQ -154 study , successfully completed  a prior  
ARQ-154 study through the final visit and  are able to 
immediately enroll into this long -term safety study on the final 
visit of a previous ARQ-154 study.  
Inclusion Criteria : 
Cohort 2 Only For subjects that have not participated i n a prior  ARQ-154 study:  
6. Clinical diagnosis of seborrheic dermatitis of at least 3  months 
duration as determined by the Investigator.  Stable disease for 
the past 4 weeks.   
7. Seborrheic dermatitis of the scalp and/or face and/or trunk 
and/or intertriginous areas up to ≤20% BSA involvement.  
8. An Investigator Global Assessment (IGA) of disease severity of 
at least Moderate (‘3’) at Day 1.  
9. Overall Assessment of Erythema and Overall Assessment of 
Scaling scores of Moderate (‘2’) at Day 1.  
 For subjects that have completed a prior  ARQ-154 study prior to 
initiation of the current ARQ -154-214 study:  
10. Clinical diagnosis of seborrheic dermatitis of at least 3  months 
duration as determined by the Investigator.   
11. Seborrheic dermatitis of the scalp and/or face and/or trunk 
and/or intertriginous areas up to ≤20% BSA involvement.  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 13 of 73   
Exclusion Criteria : 
Cohort 2 Only 17. Previous participation in this ARQ-154-214 study.  
15. Subjects who cannot discontinue treatment with therapies for the 
treatment of seborrheic dermatitis prior to the Day 1 visit and 
during the study according to Excluded medications and 
Treatment ( Table  1). 
16. Subjects with PHQ -8 >10 or modified PHQ -A >10 at Screening 
or Day 1.  
For subjects that have completed a prior  ARQ-154 study prior to 
initiation of the current ARQ -154-214 study: 
18. Subjects who experienced an ARQ-154 treatment -related AE or 
a serious AE (SAE) that precluded further treatment with 
ARQ-154 foam.  
Duration of Participation 
for Subjects:  Up to a pproximately 52 weeks 
Key Assessments:  Safety will be monitored through application site assessments, safety 
labs, vital signs, physical examinations, clinical laboratory testing, 
and Adverse Events (AEs). Safety will also be monitored by C -SSRS 
(for adolescents and adults 12 years old and older), Children’s 
Depression Inventory 2 (CDI -2, parent report for children 9-11 years 
old, inclusive), PHQ-8 (in adults) and modified PHQ -A 
(in adolescents 12-17 years old, inclusive ) assessments.  
Efficacy assessments will include IGA, Overall Assessment of 
Erythema, Overall Assessment of Scaling, WI -NRS, Scalpdex, and 
BSA.  
Study Endpoints:  Primary Endpoints  
• Occurrence of treatment emergent AEs (TEAEs)  
• Occurrence of Serious Adverse Events (SAEs)  
Secondary Endpoints  
• Achievement of an Investigator Global Assessment (IGA) of 
‘completely clear’ or ‘almost clear’, as observed over time  
• A 2-grade improvement in IGA from Baseline  
(see Section 7.1.1 ) as observed over time 
• ‘IGA Success’, defined as achievement of an IGA of 
‘completely clear’ or ‘almost clear’ plus a 2 -grade 
improvement in IGA from Baseline (see Section 7.1.1 ) as 
observed over time  
• Duration of IGA Success, defined as the time from the first 
observation of IGA Success to the last time a subject’s 
disease response meets the criteria for IGA success.  The 
duration of IGA Success for subjects who end treatment in 
IGA Success will be censored at the last disease assessment 
date 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 14 of 73   
• Treatment -free interval, defined among subjects who achieve 
a 'completely clear' IGA and stop treatment to all lesions  as 
the time from attainment of a score of ‘ completely clear’ to 
re-starting IP.  
Statistical Considerations : Up to  approximately  410 subjects total across Cohorts are planned 
for this study.   
The sample size will be sufficient to evaluate the long -term safety of  
ARQ-154 foam 0.3% up to 52 weeks of treatment.  
Descriptive statistics will be presented for the endpoint  and safety  
data collected in the clinical trial. This includes the number and 
percentage of subjects for binary endpoints/  categorical data, and 
mean, SD, median, Q1, Q3, minimum, and maximum for continuous 
data.    
Adverse Events 
For the primary endpoints, the occurrence of treatment -emergent AEs 
(TEAEs)  and the occurrence of Serious Adverse Events (SAEs) will 
be tabulated by preferred term and system organ class.   
In addition, summary tables of TEAEs by severity, by relationship to 
investigational product, and those leading to withdrawal from 
investigational product will be created.  
Vital Signs  
Descriptive statistics will be calculated for vital signs and change 
from baseline and percent change from baseline in vital signs  over 
time.  
Clinical Laboratory Results  
Descriptive statistics of the laboratory parameters will be calculated 
at each scheduled time point.  Change from Baseline and percent 
change from Baseline will be summarized at each scheduled time 
point. Shifts from Baseline will be tabulated . 
Patient Health Questionnaires  
PHQ-8 /PHQ -A/CDI -2 and C -SSRS questionnaires will be completed 
by the subjects at all study visits. Descriptive statistics will be 
calculated  for the PHQ-8 /PHQ -A/CDI -2. The C-SSRS will be 
analyzed per the Scoring and Data Analysis Guide from the 
Columbia Lighthouse Project.  
Descriptive statistics will be presented for the efficacy  data collected 
in the clinical trial for the subjects who enroll in this study and 
receive at least one day of IP. For the binary endpoints related to 
IGA, the proportions of subjects achieving each endpoint will be 
tabulated at each scheduled visit. For subjects who withdraw from 
study due to lack of efficacy . 
The duration of response and treatment-free interval  will be analyzed 
using the Kaplan -Meier method.  
 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 15 of 73  1.2. Study S chema  
 
                                     
 
     Cohort 1 Day 1  
Final visit of prior  
ARQ-154 study 
  
Day 1  
First Day of Treatment  
  
Up to 52 -Week Treatment Period (Visits 1, 2, 3, 4 & 5)  
Phone Visit at Weeks 18, 30 & 44 
  
A Phase 2, Multicenter, Open -Label Study of the Long -Term Safety of 
ARQ-154 Foam 0.3% in Subjects with Seborrheic Dermatitis 
 
Up to Approximately 410  subjects total across two cohorts with seborrheic 
dermatitis will be receive ARQ -154 foam 0.3%. Cohort 1 will consist of 
roll over subjects from a prior ARQ-154 study on the final  visit and  
Cohort 2 will consist of subjects that may or may not have participated on in a prior ARQ-154 study.  
Cohort 2 Screening 
  
Protocol ARQ-154-214 Arcutis Biotherapeutics, Inc. 
Amendment 2 
 
04 November 2021 Confidential Page 16 of 73 1.3. Schedule of Visits and Assessments 
Study Procedure Washout 
Cohort 2 Day 1 
(Cohort 2) Wk 4 
D 29 Wk 12 
D 85 Wk 18 
D 127 Wk 24 
D 169 Wk 30 
D 211 Wk 36 
D 253 Wk 44 
D 309 Wk 52/ 
ET 
D 365 
Visit Screening Final Visit 
of prior 
ARQ-154 
Study l 
(Cohort 1) 1 2 Phone 
Visit 3 Phone 
Visit 4 Phone 
Visit 5 
Visit Window -35 days +/- 3 
days +/- 5 
days +/- 7 
days +/- 7 
days +/- 7 
days +/- 7 
days +/- 7 
days +/- 7 
days 
Informed 
consent/assent Xk Xk         
Physical 
examinationa X Xl    X    X 
Medical history X          
I/E criteria X X         
Hematology, Serum 
Chemistries, and 
Urine Analysis  X Xl X X  X  X  X 
Vital signs, height, 
weightb X Xl X X  X  X  X 
IGAc, Overall 
Assessment of 
Erythemac, Overall 
Assessment of 
Scalingc , WI-NRS, 
Scalpdex X Xl X X  X  X  X 
BSA X Xl    X  X  X 
C-SSRS, PHQ ‑8/ 
PHQ-A/CDI-2d  X Xl X X  X  X  X 
Pregnancy teste X Xl X X  X  X  X 
Local Tolerability 
Assessmentf  Xl X X  X  X  X 
Pigmentation 
Assessmentg X Xl X X  X  X  X 
Medical 
Photographyh  X X X  X  X  X 
Dispense study 
medication kiti  X X X  X  X   
IP application at the 
study site  X         
Dispense/review 
diary  X X X  X  X  X 
Protocol ARQ-154-214 Arcutis Biotherapeutics, Inc. 
Amendment 2 
 
04 November 2021 Confidential Page 17 of 73 Study Procedure Washout 
Cohort 2 Day 1 
(Cohort 2) Wk 4 
D 29 Wk 12 
D 85 Wk 18 
D 127 Wk 24 
D 169 Wk 30 
D 211 Wk 36 
D 253 Wk 44 
D 309 Wk 52/ 
ET 
D 365 
Visit Screening Final Visit 
of prior 
ARQ-154 
Study l 
(Cohort 1) 1 2 Phone 
Visit 3 Phone 
Visit 4 Phone 
Visit 5 
Visit Window -35 days +/- 3 
days +/- 5 
days +/- 7 
days +/- 7 
days +/- 7 
days +/- 7 
days +/- 7 
days +/- 7 
days 
Weigh study 
medication  X X X  X  X  X 
Adverse event 
assessmentj X X X X X X X X X X 
Concomitant 
medications X X X X X X X X X X 
PK Samplingm   X        
Malassezia testn   X X  X  X  X 
a Limited physical examination: skin, lungs, and heart only. 
b Height will be collected at Day 1, Week 24 and Week 52/ET only. Weight will be collected at all study visits. 
Subject to void prior to weight being taken. Remove any jackets, outerwear and shoes. Remove any objects of significant weight (i.e. cell phones, wallet, key chains). A 5% unintentional weight loss from Baseline should be 
reported to the medical monitor. 
c IGA will be a 5-point scale ranging from completely clear  (0) to severe (4). IGA should be completed prior to 
other physician assessments. Overall assessment of eryt hema (0-3 scale) and over all assessment of scaling 
(0-3 scale) will be completed.  Total BSA affected by seborrheic dermatitis will be determined at each visit. A 
body diagram should be used to record areas of seborrheic dermatitis involvement. 
d Adolescents and adults will complete the C-SSRS (12 year s of age and older). Adults will complete the PHQ-8. 
Adolescents (ages 12 -17, inclusive) will complete th e modified PHQ-A. Parents/ caregivers will complete CDI-
2 (parent report) for children 9- 11 years of age, inclusive. 
e A pregnancy test will be administered to all females of  child-bearing potential. A serum pregnancy test will be 
performed at the Screening visit only for Cohort 2. A urin e pregnancy test will be performed at Day 1, Weeks 4, 
12, 24, 36 and 52. A negative result is required for continued participation in the study, and results must be available prior to dispensing of IP at each visit. 
f Local tolerability will be assessed prior to IP application in the clinic for the Investigator assessment of skin 
(Berger and Bowman skin irritation score) and 10-15 minutes post IP application for the subject’s ‘0-3’ burning/stinging assessment at Baseline.  Note for Investigator tolerability assessments: reactions at the site of 
product application, which may occur post-Baseline, should be differentiated from the preexisting 
inflammation associated with th e subject’s seborrheic dermatitis .
  At Weeks 4, 12, 24, 36, and 52 will be a 
recall assessment of burning/stinging experienced post drug  application on the previous day of the clinic visit.  
g An assessment for hypopigmentation and hyperpigmentation will be performed by the investigator at all clinic 
visits. 
h At selected sites, medical photography will be obtained fo r target lesions. All efforts will be made to de-identify 
the subjects. Subjects who are unwilling to participate in the medical photography will be allowed to opt out of 
this procedure. 
i Kits will be dispensed based on %BSA aff ected. See IP Handling Manual for details.   
j Any emergent AEs will be followed in the clinic for up  to one month at the Investigator’s discretion until 
resolved or otherwise judg ed as clinically stable. 
k For Cohort 1, the consent will be signed after completion of the final visit in prior ARQ-154 study. Cohort 2 will sign consent prior to any study-related procedures at the Screening Visit.  
  
Protocol ARQ-154-214 Arcutis Biotherapeutics, Inc. 
Amendment 2 
 
04 November 2021 Confidential Page 18 of 73 l For Cohort 1, this data will be obtained from the fina l visit of the prior ARQ-154 Study and used as the Day 1 
data for this long-term safety study (ARQ-154-214). If after the prior ARQ-154 study completion, subjects 
should complete the screening visit procedures. The Base line values for Safety tabulations will be taken from 
the day that the subject received their first active IP (across prior ARQ-154 studies and ARQ-154-214). 
Baseline values for efficacy will be those recorded on  Day 1 of the prior ARQ-154 Study. For Cohort 2, 
Baseline evaluations will be obtained for all procedures  and the Baseline/Screening version of the C-SSRS will 
be utilized at Screening.  For Cohort 2, Screening labs that are collected within 14 days of Day 1 do not need to be repeated.  
m For Cohort 2 adolescent subjects PK samples will be  collected on Week 4 for adolescent subjects between 
12 – 16 years old. Collect PK sample with the safety lab collection. Ensure PK will not be drawn on the area 
where investigational product is applied. 
n At select sites, the Investigator will collect samples for Malassezia  testing on Cohort 1 Group 2 subjects at 
Weeks 4, 12, 24, 36, and 52. Samples will be collected fr om treated and untreated areas by swabbing the skin 
surface. Samples should be collected  from the same areas as sample s collected during the ARQ-154-116 
Baseline visit. 
 
 
  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 19 of 73  2. ABBREVIATIONS  
Abbreviation Definition 
AE Adverse Event  
AMP  Adenosine Monophosphate  
AUC  Area Under the Curve 
BSA Body Surface Area  
Cmax Maximum Concentration  
CDI Children’s Depression Inventory  
COPD  Chronic Obstructive Pulmonary Disease 
CRF Case Report Form  
C-SSRS Columbia -Suicide Severity Rating Scale  
CTCAE Common Terminology Criteria for Adverse Events  
FDA  U.S. Food and Drug Administration  
FOCBP Female of Child Bearing Potential 
GCP  Good Clinical Practices  
IB Investigational Brochure  
IC50 Half Maximal Inhibitory Concentration  
ICF Informed Consent Form  
ICH  International Conference on Harmonisation  
IGA Investigator Global Assessment  
I-IGA  Intertriginous IGA  
IND Investigational New Drug  
IRB Institutional Review Board  
ITT Intent to Treat 
IWRS Interactive Web Response System  
LED  Light Emitting Device  
µg Microgram  
MedDRA  Medical Dictionary for Regulatory Activities  
mL Milliliter  
NCI National Cancer Institute 
NIH National Institutes of Health  
NOAEL  No Observed Adverse Effect Level  
Ng Nanogram  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 20 of 73  Abbreviation Definition 
NRS  Numerical Rating Score  
PASI Psoriasis Area and Severity Index  
PDE -4 Phosphodiesterase 4  
PHQ-A Modified PHQ -9 for Adolescents  
PHQ-8 Patient Health Questionnaire depression scale  
PI Principal Investigator  
PK Pharmacokinetics  
QD Once Daily ("quaque die") 
SAE  Serious Adverse Event  
TEAE Treatment Emergent Adverse Event  
Tmax Time to reach maximum concentration  
WI-NRS  Worst Itch – Numeric Rating Scale 
 
  
Protocol ARQ-154-214 Arcutis Biotherapeutics, Inc. 
Amendment 2 
 
04 November 2021 Confidential Page 21 of 73 3. BACKGROUND AND RATIONALE 
3.1. Introduction 
Roflumilast is a phosphodiesterase 4 (PDE-4) inhibitor approved globally to reduce the risk of 
exacerbations in patients with severe chronic obs tructive pulmonary disease (COPD) associated 
with chronic bronchitis.  Roflum ilast and its active metabolite,  roflumilast N-oxide, are high 
affinity selective inhibitors of PDE-4 (a major cyclic-3 ′,5′-adenosine monophosphate 
(cyclic AMP)-metabolizing enzyme), whose activity leads to accumulation of intracellular cyclic 
AMP.  There are four different subtypes of PDE-4: PDE-4a, PDE-4b, PDE-4c, and PDE-4d, 
each with several isoforms (splicing variants).  IC 50 values of both roflumilast and roflumilast 
N-oxide for the different PDE-4 isoforms and subtypes are mo stly sub-nanomolar and single 
digit nanomolar ( Hatzelmann 2010 ).  The PDE-4 family of enzymes are the most prevalent 
phosphodiesterases in immune cells and inhibition of PDE-4 subtypes has been associated with 
anti-inflammatory effects in  many biological systems. 
The Sponsor is developing topical roflumilas t in several formulations (ARQ-151 cream and 
ARQ-154 foam) and indications.  To date, ARQ-151 cream has been evaluated in studies in 
psoriasis and atopic dermatitis.  Additionally, tw o PDE-4 inhibitors have been marketed for 
dermatologic indications in the US  and elsewhere, including OTEZLA® as an oral therapy for 
moderate to severe plaque ps oriasis in adults and EUCRISA® as a topical therapy for mild to 
moderate atopic dermatitis  in individuals 2 years of age and older.   
Seborrheic dermatitis is a common, chronic in flammatory skin dis ease characterized by 
erythematous, scaly plaques, often with a yello wish, oily, moist, and/or greasy appearance, 
affecting areas of sebaceous gl and abundance.  Frequently invo lved sites include the scalp 
(including retroauricular areas), eyebrows, ears, nasolabial folds, eyelids, trunk, and 
intertriginous areas.  There may be associated pr uritus and/or pigmentary changes.  Seborrheic 
dermatitis affects about 2%  of the adult population ( Borda 2015 , Dessinioti 2013 ) and occurs in 
the adolescent population as well.  It may be as sociated with certain me dications and conditions 
such as Parkinson’s disease and other neur ologic conditions, Down  syndrome, and HIV 
infection.  Seborrheic dermatitis is generally a cl inical diagnosis.  The exact cause of seborrheic 
dermatitis remains unknown.  Tr eatment of seborrheic dermatiti s may vary by location on the 
body involved, eg, scalp or non-scal p and periocular or not.  For the scalp, anti-dandruff 
shampoos are often used such as anti-fungals, zinc  products, selenium sulf ide, salicylic acid, or 
tar.  Topical corticosteroid products may also be  used.  Scalp lesions of  seborrheic dermatitis can 
present a particular treatment ch allenge and form thick crusts wh ich may not respond to topical 
steroids or antifungals.  On non- scalp regions such as the face, topical antifungals or low potency 
topical corticosteroids are typically used.  However, importantly, topical antifungals may 
demonstrate limited efficacy and topical steroi ds may demonstrate tachyphylaxis and cause 
important adverse events, particularly on the face, such as te langiectasias, acne, atrophy, rosacea, 
and ocular complications.  Since seborrheic derm atitis is a chronic cond ition, treatment with 
topical steroids is particular ly problematic due to the need  for prolonged treatment duration, 
which may result in side effects.  Other medications which have been  used for seborrheic 
dermatitis include topical sulfur/sulfonamide pro ducts, topical calcineurin  inhibitors, and oral 
retinoids. 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 32 of 73  5. INVESTIGATIONAL PLAN  
5.1. Overall Study Design and Plan 
This is an open-label, single- arm, long -term safety study  of ARQ-154 foam 0.3% in subjects 
with seborrheic dermatitis involving up to 20% total BSA. Cohort 1 eligible subjects will enroll 
into the long-term safety study on the same day as the final  visit for a previous ARQ-154 study. 
For Cohort 1, subjects will be male and female adolescents (9 -17 y/o) and adults (>18 y/o) with 
seborrheic dermatitis . Cohort 1 Group 1 will be subjects who rolled over from the prior 
ARQ-154-203 study and Cohort 1 Group 2 will be subjects who rolled over from the prior 
ARQ-154-116 study.  
Cohort 2 eligible subjects will enroll on Day 1 of this study.  For Cohort 2, subjects will be male 
and female adolescents ( 12 – 17 y/o) and adults (>18 y/o) subjects who may or may not have 
participated in a prior ARQ-154 study, i.e., either de novo subjects who did not participate in 
ARQ-154-203 or subjects who completed ARQ-154-203 prior to initiation of the current study, ARQ-154-214. 
For each Cohort, investigational product will be applied by the qualifying subjects topically QD for up to 52 weeks. Periodic clinic visits will include assessments for clinical safety, application 
site reactions evaluated in the clinic using the method of Berger and Bowman, and disease 
improvement or progression.  
Final analysis will be performed when s ubjects in Cohort 1 Group 1 and Cohort 2 
(approximately 400 subjects) finish up to 52 weeks.    
Subjects in Cohort 1 Group 2 (approximately 10 subjects) will only be summarized in the listings 
and will be updated once all Group 2 subjects finish up to 52 w eeks of treatment. A CSR 
addendum will be provided based on the updated Cohort 1 Group 2 listing.    
5.2. Number of Sites and Subjects 
A total of up to approximately 410 subjects total across both Cohorts will be enrolled at  
approximately 40 study sites in North America .  Additional countries or study sites may be 
added as necessary . Subjects in Cohort 1 will be male and female adolescents (9 -17 y/o) and 
adult s (>18 y/o)  with seborrheic dermatitis. Subjects in Cohort 2 will be ad olescent  and adult 
males or females with  seborrheic dermatitis  that may or may not have participated in a prior  
ARQ-154 study.  Subjects in Cohort 2 that have not participated in a prior ARQ-154 study (i.e., de novo  subjects)  must have an IGA of disease severity of at least Moderate (‘3’) at 
Baseline.  Subjects that completed  a prior ARQ-154 study prior to initiation of the current 
ARQ-154-214 study may be eligible to enroll in Cohort 2 of the present study , and these subjects 
may have any IGA at Day 1  of the present study.  All subjects in each Cohort must have no more 
than 20% Body Surface Area (BSA) of seborrheic dermatitis.  All lesions on a subject will be 
treated including the scalp, face, trunk, and intertriginous areas.     
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 33 of 73  5.3. Subject Participation  
Subject participation involves a minimum of 5 clinic visits at Week 4, Week 12, Week 24, 
Week  36 and Week 52 and  phone visits at Week 18 , Week 30 and Week 44 . The Day 1 visit of 
this study will be the final visit of a preceding ARQ-154 study for Cohort 1 and Day 1 of this 
study for Cohort 2 . The anticipated duration of subject participation up to approximately 
52 weeks.  
5.3.1. Numbering  of Subjects  
Cohort 1 subjects enrolled ma y retain their unique five-digit subject ID number previously 
assigned during the prior  ARQ-154 study or may be assigned a unique ID . Cohort 2 subjects will 
be numbered with the 2-digit site number and a three -digit subject number starting with 500. 
The clinical site is responsible for maintaining a current log of subject ID number assignmen ts 
and the investigational product kit numbers assigned to that subject and entering into the IRT 
system .  The subject ID number is required to be entered on all clinical study documentation 
(e.g., case report for ms, labeling of clinical materials and sample containers, investigational 
product accountability logs, etc.).   
5.4. Selection of Study Population 
5.4.1. Inclusion Criteria  
All Subjects  
Subjects must fulfill all of the following inclusion criteria to be eligible for participation in the 
study: 
1. Participants legally competent to sign and give informed consent or (for adolescents) 
assent . 
2. Males and females ages 9 years and older (inclusive) at the time of consent. 
3. Females of childbearing potential ( FOCBP) must have a negative urine pregnancy test at 
all study visits. In addition, sexually active F OCBP must agree to use at least one form of 
an acceptable effective contraception throughout the trial.  Acceptable e ffective forms of 
contraception may include: oral/implant/injectable/transdermal contraceptives, intrauterine device, or partner’s vasectomy.  If barrier methods are used (e.g., condom 
with spermicide, diaphragm with spermicide), then 2 forms of con traception are required.  
The use of abstinence as a contraceptive measure is acceptable as long as this is a consistent part of a lifestyle choice and a backup method has been identified if the subject 
becomes sexually active.  
4. Female of non -childbearing potential must be either pre -menarchal or p ost-menopausal 
women with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization (permanent sterilization methods include hysterectomy, bilateral 
oophorectomy, hysteroscopic sterilization, bilateral tubal ligation or bilateral salpingectomy).  
Protocol ARQ-154-214 Arcutis Biotherapeutics, Inc. 
Amendment 2 
 
04 November 2021 Confidential Page 35 of 73 6. Known or suspected:  
 severe renal insufficiency, or  moderate to severe hepatic disorders (Child-Pugh B or 
C) 
 history of severe depression, suicidal ideat ion or C-SSRS (for adol escents and adults 
12 years old and older) indicative of su icidal ideation, whether lifetime or 
recent/current 
7. Females who are pregnant, wishing to b ecome pregnant during the study, or are 
breast-feeding. 
8. Subjects with any serious medical condition or laboratory abnormality that would prevent 
study participation or place the subject at significant risk, as determined by the 
Investigator. 
9. Subjects with a history of chronic alcohol or drug abuse within 6 m onths of initiation of 
investigational product. 
10. Current or a history of cancer within 5 years with the exception of fully treated skin basal 
cell carcinoma, cutaneous squamous cell carcino ma or carcinoma in situ of the cervix. 
11. Subjects who are unable to communicate, read  or understand the local language, or who 
display another condition, which in the Invest igator’s opinion, makes them unsuitable for 
clinical study participation. 
12. Subjects who are family member s of the clinical study site , clinical study staff, or 
Sponsor. 
Cohort 1 Only 
13. Subjects who experienced an ARQ-154 treatment -related AE or a serious AE (SAE) that 
precluded further treatme nt with ARQ-154 foam in a prior ARQ-154 study. 
14. Subjects that use any Excluded Medications and Treatments ( Table 1 ). 
17. Previous participation in this ARQ-154-214 study. 
Cohort 2 Only 
15. Subjects who cannot discontinue treatment with therapies for the treatment of seborrheic 
dermatitis prior to the Day 1 visit an d during the study according to Excluded 
medications and Treatment ( Table 1 ). 
16. Subjects with PHQ-8 >10 or modified PHQ-A >10 at Screening or Day 1. 
For subjects that have comp leted a prior ARQ-154 study prior to initiation of the current 
ARQ-154-214 study: 
18. Subjects who experienced an ARQ-154 treatment-related AE or  a serious AE (SAE) that 
precluded further treatme nt with ARQ-154 foam. 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 36 of 73  5.4.3. Removal of Subjects from Investigational Product  
A subject may discontinue from receiving the investigational product for any of the following 
reasons:  
• Occurrence of any medical condition or circumstance that, in the opinion of the 
Investigator, exposes the subject to substantial risk and/or does not allow the subject to adhere to the requirements for investigational product administration  as per  the 
protocol. 
• Occurrence of a treatment -emergent adverse event (TEAE) or considerable worsening 
of an AE that, in the opinion of the I nvestigator in consultation with the Medical 
Monitor and Sponsor, represents an unacceptable risk to the subject if he/she continues in the study.  The I nvestigator must follow the subject until the AE resolves 
or satisfactorily stabilizes.  
• Pregnancy. 
• Subject's decision to withdraw from administration of the investigational product. 
• Weight loss of >5% from B aseline if not dieting or intentionally trying to lose weight 
and after consultation with the Sponsor, at the Investigator’s discretion.  
• C-SSRS indicative of suicidal ideation . 
• PHQ-8 or modified PHQ- A score ≥15  if determined by Investigator in consultation 
with a mental health professional . 
• CDI-2 raw score of ≥32 if determined by Investigator in consul tation with a mental 
health professional.  
• Requirement for use of prohibited concomitant medication  (see Table 1) after 
consult ation with the Sponsor and Medical Monitor. 
• Subject’s repeated failure to comply with protocol requirements or study related 
procedures. 
5.4.4. Removal of Subjects from the Study  
A subject may be removed from study participation for any of the following reasons: 
• Subject death 
• Subject’s decision to withdraw from the study. 
• Subject is lost to follow up . A subject will be considered lost to follow -up after three 
phone and three email attempts and documentation of a certified letter sent to the subject’s address.  
• Termination of the study by the Sponsor, FDA, or other regulatory authorities. 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 37 of 73  5.5. Study Restrictions  
5.5.1. Prohibitions and Concomitant Therapy  
Prohibited medications and products are detailed in Table 1.   
Table 1: Excluded Medications and Treatments  
Excluded Medications and Treatments  Wash Out Period Prior to Day 1  
Biologics  12 weeks  or 5 half -lives, which is longer  
Systemic treatment with antifungal agents, corticosteroids, 
immunosuppressive therapies, retinoids, roflumilast, or Otezla® 4 weeks  
Topical antifungals, corticosteroids, calcineurin inhibitors, sulfur -based 
treatments, medical devices, Eucrisa®, azelaic acid, or metronidazole  2 weeks  
Medicated shampoos (e .g., coal tar, keratolytics  including salicylic acid , 
antifungals, zinc pyrithione, selenium sulfide, corticosteroids, medical devices)  2 weeks  
Topic al medications used on the scalp for conditions besides seborrheic 
dermatitis, e .g., use of topical minoxidil for androgenetic alopecia  4 weeks  
Strong systemic P -450 cytochrome inhibitors  
(e.g. indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, 
ketoconazole, nefazodone, saquinavir, suboxone and telithromycin)  2 weeks  
Phototherapy, tanning beds, other light emitting devices  4 weeks  
Investigational drugs  (other than ARQ -154) 12 we eks (biologics)  or 5 half -lives, 
whichever is longer ; 
5 half -lives (orals);  
2 weeks (topical)  
Note:  Eye drop  and nasal corticosteroid preparations are allowed.  Inhaled corticosteroid preparations are allowed if 
used for a stable condition and at a stable dose for > 28 days before screening and are continued at the same dose 
throughout the study.  
Non-medicated emollients, moisturizers and sunscreens will be allowed once daily as normally used by the subjects 
and applied at least 3 hours after application of investigational product to untreated areas only.  
Generally, the addition of new medications, including nonprescription medications, during the 
course of the study is discouraged.  However, the short- term use of a medication may be 
authorized by the Investigator.  The Investigator must make the decision to authorize the use of any such a medication only after c onsideration of the clinical situation, the potential for masking 
symptoms of a more significant underlying event, and whether the use of the medication will 
compromise the outcome or validity of the clinical investigation.  If medication is required, 
the name, strength, frequency, duration of use, and reason for use will be recorded in source documents and transcribed to Case Report Forms.  Medications which have been used 
chronically by subjects, in particular statins and anti- hypertensives, are allowed f or use during 
the study, except as prohibited in ‘Exclusions’ ( Table 1).  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 38 of 73  Only non-medicated shampoos are permitted. Medicated shampoos (e.g., coal tar, keratolytics 
including salicylic acid, antifungals, zinc pyrithione, selenium sulfide, corticosteroids, medical 
devices) are prohibited.  Subjects should not use other hair products for at least an hour before or 
after application  of investigational p roduct.   
5.6. Treatment  
5.6.1. IP Supplies, Packaging and Labeling  
ARQ-154 foam 0.3% will be provided in a dispense Can containing approximately 60 gram s of 
foam.   The  Cans will be packaged in K its. The number of K its dispensed to a subject will be 
based on the BSA involvement. The K it(s) and Cans will be labeled including a location to 
record the subject ID on the label.  
The Sponsor will supply sufficient quantities of the investigational product (ARQ-154 foam 
0.3%) to each site to allow for completion of this study.  
Records will be made of the receipt and dispensing of the investigational product supplied. At the conclusion of the study, any unused investigational product will be returned to the 
Sponsor or designee, or destroyed, as per Sponsor instructions.  
Refer to the most current version of the IP Handling Manual for details on the accountability, storage, and management of ARQ -154 foam. 
5.6.2. Blinding  
This is an open -label study and no blinding is planned. 
5.6.3. Treatment  Administration  
Seborrheic dermatitis lesions that have completely resolved, in the opinion of the Investigator, do not require continued treatment. At every clinic visit the Investigator will determine if the IGA are considered ‘clear’ and the subject will stop applying the investigational product. The subject 
will contact the clinical study site and document in diary when seborrheic dermatitis returns prior 
to restarting investigational product. Subjects that clear between scheduled visits should return 
for an unscheduled visit for the I nvestigator to confirm IGA  score are considered ‘ clear ’.  
Unless otherwise instructed by the Investigator, subjects will apply investigational product once 
daily.  At the Day 1 visit, the study staff  will demonstrate to the subject how to apply ARQ -154 
foam using the first Can  from the Kit that is provided to the subject at Day 1 .  Study site staff  
will be trained to ensure a proper amount is dispensed from the foam C an and applied to 
seborrheic dermatitis  lesion (s) as a thin layer  and rubbed in thoroughly but gently, until the foam  
has disappeared.  For scalp lesions, special attention should be given to ensuring adequate 
investigational product is applied to scalp skin and not rubbed off on hair . The subje ct will 
then practice dispensing a similar amount of investigational product and applying to seborrheic 
dermatitis lesion(s).  The study staff will confirm that the subject’s application technique is 
correct.  Cohort 1 Group 2 subjects will apply the last dose of IP for ARQ -154-116 Week 2 
(Day  15) study visit; subjects will enroll in ARQ -154-214 on the same day but will start applying 
IP the following day (Day 2). The study staff will review with the subject the appropriate IP 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 39 of 73  dispensing and application technique for the ARQ-154-214 study during the Baseline visit 
(Day  1).   
IP will be applied in the evening to areas of lesions of seborrheic dermatitis.  IP will be applied at least 20 minutes before going to bed.   
For Scalp Lesions: IP will be applied when the skin and hair on the scalp is dry.  Subjects should 
dispense IP on their fingers, then part hair where there are lesions and rub IP in to scalp skin . As 
the IP is applied, the subject should move any hair away to ensure that sufficient foam is actually 
applied directly to the affected skin on the scalp. Subjects should not use other hair products for 
at least an hour before or after application.   
For Non- scalp Lesions: IP should be applied to affected areas as a thin layer  and rubbed in 
thoroughly but gently until the foam has disappeared.   
Re-training will be conducted at subsequent visits as needed ( i.e., if the returned Can (s) weighs 
substantially different than the expected weight). 
Subjects should not wash areas (or otherwise expose to water, e.g., swimming) where ARQ-154 
foam or vehicle has been applied  until at least 4 hours after IP  application and preferably not 
until the following morning.    
Subjects should continue to apply investigational product to all active seborrheic dermatitis 
lesions including any new lesions that develop during the study unless otherwise instructed by 
the Investigator. Application will be to all areas affected including the face , scalp  and 
intertriginous  areas. A Body and Scalp Diagram should be used to record existing and new areas 
of seborrheic dermatitis involvement that are subject to treatment.  
Each IP C an will be weighed prior to dispensing at the Day 1  visit or  subsequent visits. IP Cans 
must be returned by subjects at each study visit, both e mpty and full , and will be weighed 
individually . If the subject ’s actual  use is substantially  different than the expected use for the 
subject’s BSA (see IP Handling Manual ), the subject will  be retrained on the IP  application 
technique. 
5.6.4. Treatment Compliance  
Weight of the IP  applied will be measured for reporting purposes.  Each IP Can will be weighed 
individually at each follow -up clinic visit and recorded in the source notes and in the eCRF.  
Subjects will complete a daily  diary recording the date and time of each dose applied, any missed 
doses, and a comment section should the subjects have a comment, e.g., record potential Adverse 
Events (AEs) . Site personnel will review the diaries at each clinic visit and use the information to 
question the subject regarding compliance and AEs and then record appropriate information in 
source documents and complete Case Report Forms ( CRFs ).  If a subject misses a scheduled  
dose, they should be instructed to return to the protocol IP administration schedule  (i.e. if subject 
forgets a dose they should wait until that evening and apply as usual).   
A subject will be considered compliant with the dosing regimen if the subject applies at least 
80% of the expected applications during the IP  application p eriod and does not miss more than 
3 consecutive doses.  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 40 of 73  Compliance will be assessed by review of the dosing diary. If the diary shows less than 80% of 
expected use, the subject is using too little IP  and retraining must be conducted and documented.  
Compliance will be documented in source and in eCRF.  
6. STUDY PROCEDURES  
6.1. Safety Assessments 
The Schedule of Visits and Assessments ( Section 1.3) summarizes the clinical procedures to be 
performed at each visit. Individual clinical procedures are described in detail below. Additional evaluations/testing may be deemed necessary by the Investigator and/or the Sponsor for reasons 
related to subject safety.  
This stu dy assesses the safety and efficacy  of ARQ-154 foam . Safety will be determined by 
evaluating physical examinations, local tolerability  assessments, vital signs/weight , clinical 
laboratory parameters, PHQ -8/PHQ-A /CDI -2, C- SSRS and AEs as outlined in the Schedule of 
Visits and Assessments ( Section 1.3 ). If deemed necessary, additional safety assessments will be 
performed at the discretion of the Investigator. 
Screening  Visit (Cohort 2)  
Within 35 days prior to the first dosing ( Day 1 ), subjects will be provided details of study 
requirements and sign an informed consent.  Medical history and demographic data including 
sex, age, race, ethnicity, body weight (kg), and height (cm) will be recorded.  Each subject will 
undergo seborrheic dermatitis  assessments,  a physical examination, vital sign measurements 
(blood pressure, heart rate , and temperature ), PHQ-8/PHQ-A, C- SSRS, and laboratory tests: 
hematolog y, chemistry , urinalysis and serum pregnancy tests for female subjects  of childbearing  
potential. 
All screened subjects will receive a screening number according to Section 5.3.1 and be entered 
into the IRT system  and eCRF . Subjects that fail to  meet the eligibility crit eria will be designated 
as a screen failure and entered into the IWRS and eCRF as such.  
Subjects may be re-screened one time, the original assigned Subject ID screening number will be used for re -screening.  
Day 1 Visit 
For Cohort 1, at Day 1 ( Final visit o f the prior ARQ-154 study) subjects will be provided details 
of study requirements and sign an informed consent.  Each subject will undergo seborrheic 
dermatitis assessments,  a physical examination, vital sign measurements  (blood pressure, heart 
rate, and temperature),  PHQ-8/PHQ -A/CDI -2, C- SSRS, and laboratory tests : hematology, 
chemistry, urinalysis and urine pregnancy tests for female subjects of child bearing potential will 
be obtained at the final visit of the prior ARQ-154 study and will serve as Day 1  for Cohort 1 
subjects. Cohort 2 Day 1 assessments for this long -term safety study (ARQ -154- 214) will be 
completed within 35 days of Screening. 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 41 of 73  For Cohort 2, i f the Day 1 visit occurs within 14 days of Screening, the Screening lab results may 
be utilized.  Cohort 2 subjects must meet the required wash out period for any excluded 
medications and treatment according to Table 1.  
IP will be dispensed  at the Day 1 visit (via IWRS) after the Investigator confirms the subject to 
be fully eligible for participation based on the study criteria listed in Section 5.4.1 and 
Section  5.4.2. A subject is considered enrolled into the study upon the first IP application.  
6.1.1. Physical Examination  
Physical examination s will be performed  according to the Schedule of Visits and Assessments 
(Section 1.3 ). The physical exam will be limited to skin, lungs and heart only. 
6.1.2. Vital Signs , Height and Weight 
Vital signs will be collected according to the Schedule of Visits and Assessments ( Section  1.3): 
Blood pressure, heart rate, and temperature  will be measured . Blood pressure will be collected 
while the subject is sitting/resting for at least 5 minutes.  
Height will be collected at Day 1 , Week 24 and end of study Week  52/Early Termination .  
Subject to voi d prior to weight being taken and remove any jackets, outerwear and shoes. 
Remove any objects of significant weight (i.e. cell phones, wallet, key chains). A 5% unintentional weight loss from Baseline should be reported to the medical monitor.  
6.1.3. Laboratory Tests 
All tests listed in  Table 2  below will be performed according to the Schedule of Visits and 
Assessments  (Section 1.3 ), unless otherwise noted. No food restrictions are required for the 
collection of specimens. In addition, laboratory safety tests may be performed at various 
unscheduled time points, if deemed necessary by the Investigator.  Laboratory samples will be 
sent to the central lab. Refer to the most current Central Laboratory Manual for collection, 
processing, ship, and report receipt instructions. 
Table 2: Laboratory Tests
 
Hematology  Serum Chemistry  
• Hemoglobin  
• Hematocrit  
• Total and differential leukocyte count  
• Red blood cell count with indices and morphology  
• Platelet count  • Blood Urea Nitrogen  
• Bilirubin (total and direct)  
• Alkaline phosphatase  
• Aspartate aminotransferase  
• Alanine aminotransferase  
• Albumin  
• Sodium  
• Potassium  
• Chloride  
• Glucose  
• Creatinine  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 42 of 73  Table 2: Laboratory Tests (Continued)  
Urinalysis  Additional Tests  
• pH 
• Specific gravity  
• Protein*  
• Glucose  
• Ketones  
• Bilirubin  
• Blood*  
• Nitrite*  
• Urobilinogen  
• Leukocyte esterase*  • Urine pregnancy test  
• (for females of childbearing potential only)  
• Serum pregnancy test (hCG)**  
• Pharmacokinetic (PK) assessments  
• Malassezia Test*** 
* If urinalysis is positive for protein, blood, nitrite, and/or leukocyte esterase, a microscopic examination (for red 
blood cells, white blood cells, bacteria, casts, and epithelial cells) will be performed.  
** At Screening only  
*** Samples collected for Cohort 1 Group 2 subjects only and may be used for Malassezia  testing.  
6.1.4. Patient Health Questionnaire depression scale (PHQ -8) 
The 8 item PHQ -8 Assessment (see Appendix 1) will be completed by adult subjects according 
to the Schedule of Visits and Assessments (Section 1.3).  
A subject with a PHQ -8 score of ‘15’ or above should be referred promptly to a mental health 
care professional and , if currently applying investigational product, consideration should be 
given to discontinuation from investigational product.   
Subjects with PHQ-8 >10 at Screening (Cohort 2 only) or Day 1  will be excluded from the study. 
PHQ- 8 score is the sum of the responses for the 8 questions.  
Five severity categories of depression are defined as follows:  
• None – Minimal depression (0 to 4)  
• Mild depression (5 to 9)  
• Moderate depression (10 to 14)  
• Moderately severe depression (15 to 19)  
• Severe depression (20 to 24) 
6.1.5. Patient Health Questionnaire depression scale ( Modified PHQ -A) 
The 8 item Modified PHQ-A Assessment (see Appendix 2 will be completed by adolescent 
subjects (12-17 years old, inclusive) according to the Schedule of Visits and Assessments 
(Section 1.3 ).  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 43 of 73  A subject with a PHQ -A score of 1 5 or above should be referred promptly to a mental health care 
professional and, if currently applying IP , consideration be given to discontinuation from 
investigational product .   
Subjects with PHQ- A >10 at Screening (Cohort 2 adolescents only) or Day 1 will be excluded 
from the study.  
Modified PHQ-A score is the sum of the responses for the 8 questions.  
Five severity categories of depression are defined as follows:  
• None – Minimal depression (0 to 4)  
• Mild depression (5 to 9)  
• Moderate depression (10 to 14)  
• Moderately severe depression (1 5 to 19)  
• Severe depression (20 to 24) 
6.1.6. Children’s Depression Inventory 2  
The CDI -2 Assessment will be performed according to the Schedule of Visits and Assessments 
(Section 1.3)  for subjects 9 to 11 years old, inclusive. 
The CDI -2 quantifies depressive symptomatology using reports from children/adolescents, 
teachers, and parents or caregivers. It is recommended for use in ini tial evaluation and is 
appropriate when there is a need for an assessment and robust description of a child’s depressive 
symptoms. 
This study will use the CDI Parent Report Form. An example of the Parent Report Form is 
presented in  Appendix 6.  
A subject with a CDI -2 raw score of > 21 for females and > 22 for males  should be referred to a 
mental health professional.  
A subject with a CDI -2 raw score of > 32 should be immediately referred to a mental health 
professional, and Investigators in consultation with the mental health professional should consider interruption or discontinuation of the IP . 
6.1.7. Columbia -Suicide  Severity Rating  Scale  (C-SSRS)  
C-SSRS Assessments will be performed according to the Schedule of Visits and Assessments 
(Section 1.3 ) for subjects 12 years old and older. 
On all visits, the Since Last Visit version ( Appendix 4) will be used for Cohort 1. Cohort 2 will 
use the Baseline -Screening version ( Appendix 3) for Sc reening and Since Last Visit version 
(Appendix 4 ) for Day 1 and all remaining visits.   
If a subject has a score greater than 0 in suicidal ideation at Screening (Cohort 2 only) or Day 1, this is important and may indicate the need for mental health intervention. The investigator 
should not enroll the subject in the study. 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 44 of 73  Any score greater than 0 in the suicidal ideation score is imp ortant and may indicate the need for 
mental health intervention  and consideration be given to discontinuation from IP . This should 
result in  prompt referral to a mental health professional and/or possibly the emergency room. 
The Medical Monitor should be contacted.  
The trained administrator will conduct the C- SSRS.  The C -SSRS administrato r will be trained 
via the C- SSRS training video. A training certificate  for the administer(s) will be on file in the 
trial master file at the site . 
An Investigator must review the completed C -SSRS.  A qualified mental health care provider 
must be available, immediately if needed, to refer the subject for further evaluation.  
6.1.8. Local Tolerability  Assessment s 
The Investigator Local Tolerability Assessment will be  an overall assessment of local 
tolerability . 
Application site reactions will be graded at the timepoints  outlined in the Schedule of Visits and 
Assessments  (Section 1.3 ).  Irritation reactions are graded using the scale detailed in the 
following section ( Berger  1982) .  Reactions at the site of product application, which may 
occur post -Baseline, should be differentiated from the preexisting inflammation associated 
with  the subject’s seborrheic dermatitis.   
The Investigator assessments will be conducted by the Investigator prior to  any investigational  
product application in the study site.  
Dermal Response 
0 = no evidence of irritation 
1 = minimal erythema, barely perceptible 
2 = definite erythema, readily visible; minimal edema or minimal papular response  
3 = erythema  and papules 
4 = definite edema  
5 = erythema, edema and papules 
6 = vesicular eruption  
7 = strong reaction spreading beyond application site 
Other Effects  
 A = slight glazed appearance  
 B = marked glazing  
 C = glazing with peeling and cracking  
 D = glazing with fissures  
 E = film of dried serous exudates  
 F = small petechial erosions and/or scabs  
G = no other effects 
The Subject Local Tolerability  Assessment will be an overall assessment of local tolerability and 
performed at the timepoints outlined in the Schedule of Visits and Assessments ( Section 1.3). 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 45 of 73  This assessment will be administered  on Day 1 at  the site  10 to 15 minutes after IP  application  at 
the study site. Assessments at the study site during Weeks 4 , 12, 24, 36 and 52 will be a recall 
assessment of the subject’s experience 10 -15 minutes after  IP application since the last study 
visit.  
Grade  Sensation Following Investigational Product Application  
0 (none)  No sensation  
1 (mild)  Slight warm, tingling sensation; not really bothersome  
2 (moderate)  Definite warm, tingling sensation that is somewhat bothersome  
3 (severe)  Hot, tingling/stinging sensation that has caused definite discomfort  
6.1.9. Pigmentation Assessment  
The Investigator w ill assess for pigmentation in areas affected previously and/or currently by 
seborrheic dermatitis at the timepoints outlined in the Schedule of Visits and Assessments 
(Section 1.3 ). 
Hypopigmentation and hyperpigmentation will be scored individually using a 0 – 3 scale: ‘0’ for  none, ‘1’ for mild, ‘2’ for moderate, and ‘3’ for severe.  
6.1.10. Adverse Events  
Adverse events (AEs) will be collected b eginning at informed consent and assessed  at the 
following visits and throughout the study according to the Schedule of Visits and Assessments 
(Section 1.3 ). 
AE collection will end upon completion of study participation for subjects who complete or early 
terminate from the study without any new or ongoing AEs. Subjects with new or ongoing related 
AEs upon study completion or early termination will be followed for up to one month after the 
end of treatment until the symptoms or clinically significant abnormal laboratory test value(s) return to normal or acceptable levels, as judged by the Investigator. 
Treatment emergent AEs will be followed in the clinic for up to one month at the Investigator’s 
discretion until resolved or otherwise judged as clinically stable.  
Refer to  Section 6.6 for further details on Adverse Events.  
6.1.11. Phone Visits  
Phone visit s at Weeks 18, 30 and 44 will be conducted for all subjects to review any adverse 
event or concomitant medication changes. 
6.1.12. Pharmacokinetic Assessment  
An optional pharmacokinetic sample will be collected during the Week 4 visit for Cohort 2 
subjects between 12 – 16 years of age. Adolescent subjects must give assent and the parent/legal 
guardian give consent for the PK collection. Collect the PK sample while the subject is having safety laboratory  sample s drawn . Ensure the PK sample is not drawn on the ar ea where IP is 
applied.   
Protocol ARQ-154-214 Arcutis Biotherapeutics, Inc. 
Amendment 2 
 
04 November 2021 Confidential Page 47 of 73 Overall Assessment of Erythema 
Symptom Score Description 
Erythema 0 None:  
1 Mild:  
2 Moderate:  
3 Severe:   
6.2.3. Overall Assessment of Scaling 
Overall Assessment of Scaling will be performed at the timepoints outlined in the Schedule of 
Visits and Assessments ( Section 1.3 ). 
Overall Assessment of Scaling are static qualitative evaluations, i nvolving an ordinal scale with 
4 severity grades (reported only in  integers of 0 to 3).  Each gr ade is defined by a distinct and 
clinically relevant morphologic description that minimizes inter-observer variability.  
Every effort must be made for the same Eval uator to complete the Overall Assessment of 
Scaling for the subject at every study visit. 
Overall Assessment of Scaling 
Symptom Score Description 
Scaling 0 None:  
1 Mild:  
2 Moderate:    
3 Severe:   
6.2.4. Body Surface Area (BSA) 
BSA Assessments will be performed at the timepoints outlined in the Schedule of Visits and 
Assessments ( Section 1.3 ). 
The BSA affected by seborrheic dermatitis will be determined by the subject’s hand method, 
where the subject’s hand (includi ng fingers) surface area is assume d to equal 1% of body surface 
area (BSA).   
6.2.5. Worst Itch Numerical Rating Scale (WI-NRS) 
Given that itch is an important symptom of seborrheic dermatitis, a WI-NRS assessment is 
included in the present study.  A responder analysis  will be performed to evaluate achievement 
of a 4-point reduction of WI-NRS, which has been described as  optimal for dem onstrating a level 
of clinically meaningful improve ment in itch severity in othe r skin conditions, including other 
forms of eczema ( Yosipovitch 2019 ) and psoriasis ( Kimball 2016 ).  
WI-NRS Assessments will be performed at the tim epoints outlined in the Schedule of Visits and 
Assessments ( Section 1.3 ). 

Protocol ARQ-154-214 Arcutis Biotherapeutics, Inc. 
Amendment 2 
 
04 November 2021 Confidential Page 48 of 73 The WI-NRS has been developed as a simple, single  item to assess the patient-reported severity 
of this symptom at its hi ghest intensity during the pr evious 24-hour period. ( Naegeli 2015 ). 
The WI-NRS will be determined by asking the subj ect’s assessment of worst itch over the past 
24 hours. The scale is from ‘0 to 10’ (“no itch”  to “worst imaginable itch”). Subjects will 
complete the WI-NRS pruritus assessment. 
 
6.2.6.  Scalpdex 
The Scalpdex will be completed at the timepoi nts outlined in the Schedule of Visits and 
Assessments ( Section 1.3 ). 
Subjects will complete the Scalpdex. See Appendix 5 for the Scalpdex. 
6.2.7.  Dermal Imaging 
Medical photography will be performed at select ed sites at Day 1, Weeks 4, 12, 24, 36 and 52 
using Canfield photography equipment. Photogra phy should be focused on single lesions or 
specific body sections (e.g. forehead). Body or half body photos should only be taken if 
necessary. All efforts will be made to de-identify the subjects. Subjects who are unwilling to 
participate in the medical photography will be allowed to opt out of this procedure and 
documented on the informed consent. Refer to th e current Photography Manu al for instructions 
regarding photography. 
6.3. Final Study Visit 
The approximate final study visit wi ll occur at the end of Week 52 of overall involvement in the 
study. The procedures performed during this visit is described in the Schedule of Visits and 
Assessments ( Section 1.3 ). A 7-day scheduling window is allowed for this visit. Adverse events 
will be recorded as reported by the subject or followed to resolution as outlined in Section 6.6.5. 
6.4. Early Termination Visit 
If a subject is withdrawn from the study, a termin ation visit will be scheduled. This visit should 
include the procedures and assessme nts that would be performed at the Week 52 visit. It will be 
noted in the database which subjects have completed the study and which were early 
terminations. 
6.5. Unscheduled Visit 
Subjects that clear between scheduled visits s hould return for an unscheduled visit for the 
Investigator to confirm IGA score are considered ‘clear’ and subject will stop application of 
investigational product af ter Investigator confirmation. S ubjects will call the site when 
seborrheic dermatitis returns prior to restar ting application of i nvestigational product. 
Unscheduled visits may also be necessary to repeat testing followi ng abnormal laboratory 

Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 49 of 73  results, for follow -up of AEs, or for any other reason, as warranted in the judgment of the 
Investigator .  
The following information will be collected for all subjects:  
• AEs 
• Concomitant medication s/procedures  
The following information will be collected for those subjects that had stopped s tudy medication 
but are experiencing a reoccurrence of seborrheic dermatitis. These subjects may have an 
unscheduled visit (although an unscheduled visit is not required as subjects only need to call the 
site) when seborrheic dermatitis returns prior to restarting application of investigational product:  
• IGA 
An updated Body Diagram of seborrheic dermatitis involvement should be provided to the subject. 
6.6. Adverse  Events 
6.6.1. Adverse Event  Definition  
An AE  means any untoward medical occurrence associated with the use of a drug in humans, 
whether or not considered drug related. An AE can therefore be any unfavorable and unintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) pro duct, whether or not related to the medicinal 
(investigational) product.   
AEs will be collected following informed consent of the subject through subject study completion.  
A treatment emergent adverse event (TEAE) is defined as an AE that started post application of 
IP at the Day 1 visit through study completion.  
Application site reactions will be considered adverse events if they require intervention, 
suspension or discont inuation of IP .  
6.6.2. Serious Adverse Event  
The definitions and reporting requirements of Health Canada/the Food and Drug Administration 
(FDA)/ ICH Guidelines for Clinical Safety Data Management , Definitions and Standards for 
Expedited Reporting, Topic E2A will be adhered to. If any AEs are serious, as defined by 
ICH Guidelines for Clinical Safety, required procedures will be followed.  
All SAEs will be reported to the Sponsor via fax or e -mail within 24 hours of becoming aware of 
the event, whether or not the SAEs  are deemed drug -related. refer  to the Safety Reporting 
Instructions  for details on how to submit the SAE Report. All serious event reporting will adhere 
to ICH E6: Guideline for Good Clinical Practice and ICH E2A: Clinical Safety Data 
Management: Defini tions and Standards for Expedited Reporting.:  The IRB  will be notified of 
the Alert Reports as per  FDA,  ICH and the IRB’s policies and procedures. 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 50 of 73  An SAE is any AE that in the view of either the PI or Sponsor, results in any of the following 
outcomes:  Death, a life -threatening AE, inpatient hospitalization or prolongation of existing 
hospitalization, a persistent or significant incapacity or substanti al disruption of the ability to 
conduct normal life functions, or a congenital anomaly/birth defect.  I mportant medical events 
that may not result in death, be life-threatening, or require hospitalization may be considered 
serious when, based upon appropri ate medical judgment, they may jeopardize the subject and 
may require medical or surgical intervention to prevent one of the outcomes listed in the above 
definition. Examples of such medical events include allergic bronchospasm requiring intensive 
treatmen t in an emergency room or at home, blood dyscrasias or convulsions that do not result in 
inpatient hospitalization, or the development of drug dependency or drug abuse.  
Life-threatening is defined as an AE that in the view of the PI or Sponsor, places the subject at 
immediate risk of death. It does not include an AE that, had it occurred in a more severe form, 
might have caused death. 
Hospitalization does not include the following: 
• Rehabilitation facilities, hospice facilities  or respite care (e.g. caregiv er relief)  
• Nursing homes or skilled  nursing facilities  
• Emergency room visits  
• Same day surgeries (as outpatient/same day/ambulatory procedures)  
• <24 hour admissions for observation or evaluation 
Hospitalization or prolongation of hospitalization in the absence of a precipitating, clinical AE is 
not in itself an SAE.  Examples include:  
• Admission for treatment of a preexisting condition that did not worsen  
• Hospitalizations for cosmetic elective surgery, social, and/or convenience adm issions 
• Pre-planned treatments or surgical procedures should be noted in the Day 1  
documentation for the individual subject. 
• Diagnostic and therapeutic procedures, such as surgery, should not be reported as AEs; however, the medical condition for which the procedure was performed should 
be reported if it occurs during the reporting period and meets the definition of an AE.  For example, an acute appendicitis that begins during the AE reporting period should 
be reported as an AE, and the resulting appendectomy should be recorded as treatment of the AE.  
Unexpected is defined as an AE that is not listed in the IB or is not listed at the specificity or 
severity that has been observed; or is not consistent with the risk information described in the 
general invest igational plan or elsewhere in the  current IND /CTA. 
If a SAE occurs to a subject  on this study, contact the Medical Monitor within one business day 
of knowledge of event.  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 51 of 73  6.6.3. Suspected Unexpected Serious Adverse Reaction (SUSAR)  
This is defined as a serious adverse reaction , the nature or severity of which is not consistent 
with the known study treatment information. A serious event or reaction is not defined as a 
SUSAR when: ‘it is serious but expected’ or it does not fit the definition of an SAE, whether 
expected or not.  
6.6.4. Safety Review 
At each follow -up visit, subjects will be queried with an open-ended question such as: 
‘How have you been feeling since your last visit?’  Additionally, the study staff  will review 
subject diaries and, if it appears that a potential AE was recorded, study staff will query the 
subject and determine if an AE occurred.   
AEs (whether serious or non- serious) and clinically significant abnormal laboratory test value(s) 
will be evaluated by the Investigator and treated and/or followed up for up to one month after 
end of treatment until the symptoms or value(s) return to normal, or acceptable levels, as judged 
by the Investigator. 
Where appropriate, medical test(s) and/or examination(s) will be per formed to document 
resolution of event(s). Outcome may be classified.  
6.6.5. Adverse Event Reporting  
The Investigator will review each event and assess its relationship to drug treatment (unrelated, 
unlikely, possibly, probably, lik ely). Each sign or symptom reported will be graded on the most 
current version of the NIH  NCI CTCAE toxicity grading scale 5-point severity scale (Grade 1, 2, 
3, 4 and 5). The date and time of onset, time relationship to drug dosing, duration, and outcome of each event will be noted.  
The relationship  of each AE to the IP  will be assessed using the following definitions:  
Unrelated  • The AE must clearly be caused by the subject ’s clinical state, or the study 
procedure/conditions.  
• Definitely not related to drug.  
• Temporal sequence of an AE ons et relative to administration of drug not reasonable.  
• Another obvious cause of an AE.  
Unlikely  • Time sequence is unreasonable.  
• There is another more likely cause for an AE.  
Possibly  • Corresponds to what is known about the drug.  
• Time sequence is reasonable.  
• Could have been due to another equally, likely cause.  
Probably  • Is a known effect of the drug.  
• Time sequence from taking drug is reasonable.  
• Ceases on stopping the drug.  
• Cannot be reasonably explained by the known characteristics of the subject ’s clinical 
state.  
Likely  • Is a known effect of the drug (e.g., listed in Physicians' Desk Reference, Compendium of 
Pharmaceuticals and Specialties, IB).  
• Time sequence from taking drug is reasonable.  
• Event stops upon stopping drug, event returns upon restarting drug.  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 52 of 73  The following CTCAE toxicity grading scale 5- point severity scale  definitions for rating 
maximum severity will be used: 
Grade 1  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention 
not indicated.  
Grade 2  Moderate; minimal, local or noninvasive intervention indicated; limiting age -appropriate 
instrumental activities of daily living.*  
Grade 3  Severe or medically significant but not immediately life -threatening; Hospitalization or 
prolongation of hospitaliza tion indicated; disabling; limiting self -care activities of daily 
living.**  
Note : An experience may be severe but may not be serious, e.g.,  severe headache).  
Grade 4  Life-threatening consequences; urgent intervention indicated.  
Grade 5  Death related to A E. 
Note:  A semi -colon indicates ‘or’ within the description of the grade.  
*Instrumental activities of daily living refer to preparing meals, shopping for groceries or clothes, using the 
telephone, managing money, etc.  
**Self -care activities of daily living refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
AEs will be coded using the most current MedDRA® version available  at the start of the study  
(e.g., 21.0 or higher). 
6.7. Reporting Pregnancy 
During study  participation , all subjects should be instructed to contact the Investigator 
immediately if they suspect they might be pregnant (e.g., missed or late menstrual period).  
If pregnancy is confirmed, Investigational Product must be discontinued immediately , the subject 
should be referred to an obstetrician experienced in reproductive toxicity for evaluation and 
counseling, and the subject should be followed until the conclusion of the pregnancy.   
The Investigator is responsible for reporting all available pregnancy information on the 
pregnancy report and submitting to the Medical Monitor within 24 hours of becoming aware of 
the event, although pregnancy itself is not considered an AE.  Follow-up informa tion detailing 
the outcome of the pregnancy and the health of the newborn should be reported as it becomes 
available.  In addition, any pregnancy resulting in a congenital abnormality or birth defect of the 
newborn, or neonatal death occurring within 30 days of the birth must be reported as a SAE, regardless of causality. Any infant death that occurs after the 30-day reporting period that the 
Investigator suspects is related to the Investigational Product must also be reported as a SAE.    
Partner pregnancies of a male subject do not need to be reported. 
6.8. Treatment Stopping Rules 
If a subject has non -cutaneous adverse events of concern, clinically significant laboratory values 
or any condition that the Investigator determines could possibly be related to the IP, the Investigator should immediately contact the Medical Monitor to discuss if the subject should be discontinued from the investigational product .   
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 53 of 73  Treatment for any individual subject will be discontinued if the subject:  
• Experiences a serious adverse event (SAE) or a clinically significant non -serious AE 
which in the opinion of the Principal Investigator or Medical Monitor warrants 
discontinuation from the IP  for that subject’s well-being. 
• A severe (Grade 3) laboratory abnormality (confirmed by repeat sample and 
considered related to IP ).  
Dosing of IP  for an individual subject may be suspended for safety concerns other than those 
described above, at the discretion of the I nvestigator if he/she feels the subject’s safety may be 
threatened. 
A subject with a PHQ -8 or modified PHQ -A score of 1 5 or above should be referred  promptly to 
a mental health care professional and consideration be given to discontinuation from IP.   
A subject with a CDI -2 raw total score of 32 or above should be referred to a mental health 
professional, and Investigators in consultat ion with the mental health professional should 
consider interruption or discontinuation of the IP .  
• Subjects with a CDI -2 raw score of 21 or above in females and 22 or above in males 
should be referred to a mental health professional for evaluation  
A subje ct that is  experiencing suicidal ideation and behavior should be referred  immediately to a 
qualified mental health care provider and consideration given to discontinuation from IP. 
As noted above, study treatment must be discontinued immediately in the event of a female 
subject ’s pregnancy.   
Treatment should be interrupted: 
• If a subject develops an application site reaction with the clinical appearance of an ‘irritation reaction’, and with a severity of a Dermal Response Score of 5 (erythema, 
edema and papules) or greater on the scale of Berger and Bowman, treatment should 
be interrupted for up to one week and may then be resumed if the reaction has, in the opinion of the Investigator, adequately r esolved.   
Treatment should be discontinued: 
• If the reaction reoccurs, treatment should be discontinued permanently, and the subject followed until the reaction  resolves.  Given the excellent local toler ation  in the 
Phase 1/2a study, such reactions are possible, but unlikely. 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 54 of 73  7. DATA ANALYSIS  
Data will be handled and processed according to the Contract Research Organization’s  Standard 
Operating Procedures, which are written based on the principles of GCP. 
7.1. Statistical Methods  
The methodology presented below is a summary of the more detailed analysis plan that will be 
presented in the Statistical Analysis Plan (SAP).   The SAP will be finalized before the database 
is locked and unblinded.  Any changes to the methods described in the final SAP w ill be 
described and justified in the clinical study report.  
All statistical processing will be performed using SAS ® (Version 9.4 or later ) unless otherwise 
stated.  
Descriptive statistics will be used to provide an overview of the safety and efficacy  results.  For 
categorical parameters, the number and percentage of subjects in each category will be 
presented. The denominator for percentage will be based on the number of subjects appropriate for the purpose of analysis.  For continuous parameters, descriptive statistics will include n 
(number of subjects), mean, standard deviation (SD), median, Q1, Q3, minimum, and maximum.  
No missing efficacy or safety data will be imputed  unless specified otherwise. The observed 
values will be used in the analysis.  
The final analysis will be conducted after all treated subjects in Cohort 1 Group 1 and Cohort 2 
have had the opportunity to be followed to the W eek 52 assessment.  Once all treated subjects in 
Cohort 1 Group 2 have had the opportunity to be followed to the Week 52 assessment, listings 
for these subjects will be provided for the CSR addendum.  
7.1.1. Baseline Definition  
For subjects in Cohort 1, the baseline value for safety and efficacy parameters will be define d as 
the last observation prior to the first dose of ARQ -154 foam 0.3% in either the prior ARQ-154 
study or this study (See Section 7.2.1 for the definition of a trea tment emergent event) .  
Additional analyses will be performed where in the baseline value for subjects in Cohort 1 is 
defined as the last observation prior to the first dose of ARQ -154 foam 0.3% in this study.  For 
the purpose of  these latter analyses, study procedures will not be repeated; the information from 
the prior ARQ-154 study final visit will be carried over to the Day 1 visit for this study.   
For subjects in Cohort 2, baseline values for efficacy and safety will be defi ned as the last 
observation prior to the first dose of ARQ -154 foam 0.3% in this study. 
7.1.2. Determination of Sample Size  
A sample size of  up to approximately 410 subjects is planned for the study. Th is sample size will  
provide a sufficient population size to evaluate the long- term safety of ARQ -154 foam 0.3% over 
52 weeks of treatment, and in the combination with other studies provide the development 
program with sufficient numbers of subjects to meet ICH exposure goals. 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 55 of 73  7.1.3. Subjects to Analyze  
All analyses will be  performed using the Safety Population which includes all subjects who are 
enrolled and received at least one confirmed dose of ARQ-154 foam 0.3% in this safety study. 
The number of subjects included in the Safety Population will be summarized. 
Subjects in Cohort 1 Group 2 will be summarized in listings only.  
7.1.4. Interim Analysis  
No interim analysis will be performed . 
7.1.5. Background and Demographic Characteristics 
Baseline disease characteristics an d vital sign information will be summarized descriptively for 
all enrolled  subjects.  
7.1.6. Study Disposition  
Number of subjects enrolled , receiving investigational product, completing study, and 
withdrawing prematurely (with reason for withdrawal) will be summa rized . 
7.1.7. Protocol Deviations and Eligibility Deviations  
The number of subjects with important protocol deviations and/or eligibility deviations will be 
summarized .   
7.1.8. Investigational Product  Compliance  
The number of investigational product applications by eac h subject will be summarized using 
descriptive  statistics.  
The amount of investigational product used by each subject based on Can weight will be 
summarized using descriptive statistics .   
Investigational product compliance will be calculated based on number of applications and 
amount of IP  used divided by the expected number (amount) of study medication for each 
subject.  Compliance will be summarized descriptively . 
7.2. Safety Evaluation  
Descriptive statistics will b e calculated for safety data and presented by scheduled study visit for 
quantitative safety data and frequency counts will be compiled for classification of qualitative 
safety data. Summaries of local tolerability will be presented by scheduled study visit . 
7.2.1. Adverse Events  
All treatment-emergent AEs occurring during the study will be recorded and classified on the 
basis of MedDRA terminology for the safety population. Treatment- emergent AEs are those AEs 
with an onset on or after the first date of study trea tment in this study. All treatment -emergent 
AEs will be summarized by treatment group, the number of subjects reporting treatment-emergent AEs, system organ class, preferred term, severity, relationship, and seriousness.  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 56 of 73  Serious adverse events (SAEs) will be listed by subject. SAEs will be summarized by treatment 
group, severity, and relationship to study treatment.  
For AEs, e ach subject will be counted only once within a system organ class or a preferred term 
using the e vent with the greatest relationship and greatest severity.  
All information pertaining to AEs noted during the study will be listed by subject, detailing the 
verbatim description given by the Investigator, preferred term, system organ class, start date, 
stop date, severity, action taken regarding IP , corrective treatment, outcome, and drug 
relatedness. The event onset will also be shown relative (in number of days) to date of first 
application. In addition, a list ing of subjects who prematurely discontinue f rom the IP due to 
adverse events will also be provided.  
7.2.2. Local Tolerance Assessment s 
For both the Investigator’s and Subject’s assess ment  of the numeric application site reaction , 
scores will be summarized individually by using number and percentage of subj ects by visit , as 
well as mean/median scores.   
7.2.3. Medical History and Physical Examinations  
Medical history for all subjects will be presented in a by -subject listing.  
Clinically significant changes observed during physical examination  will be captured as adverse 
events and included in AE tabulations. 7.2.4. PHQ-8 and Modified PHQ -A 
Data for PHQ -8 and Modified PHQ-A will be analyzed by a shift in state of severity using the 
following scoring system: 
• None – Minimal depression (0 to 4) 
• Mild depression (5 to 9) 
• Moderate depression (10 to 14) 
• Moderately severe depression (15 to 19)  
• Severe depression (20 to 24) 
7.2.5. C-SSRS  
The C -SSRS will be analyzed per the Columbia–Suicide S everity Rating Scale Scoring and Data 
Analysis Guide. 7.2.6. Clinical Laboratory Results and Vital Signs /Weight Measurement s 
All clinical la boratory results  and vital signs measurements and their change from baseline  and 
percent change from B aseline, will be summarized by treatment group along with  time point of 
collection.  
A shift table summarizing  out-of- normal range shifts from baseline by treatment group will be 
provided for clinical laboratory  results.  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 57 of 73  Shift table s (from baseline) by treatment group will summarize the number of subjects who gain 
or lose >5% body weight over the course of the study, as well as subjects who gain or lose >10% 
body weight over the course of the study. 
7.2.7. Prior and Concomitant Medications  
Prior and concomitant medication information for all randomized subjects will be presented in a 
by-subject listing.  Summary tables by treatment group will be presented by World Health 
Organization -Anatomical Therapeutic Chemical Classification System (WHO -ATC) therapeutic 
category and product. 
7.3. Patient Reported Outcomes Analyses  
7.3.1. WI-NRS  
Change from baseline and percent change from baseline in itch severity will be analyzed by 
treatment group and over time using the WI- NRS scale.  For subjects with WI -NRS pruritus 
score ≥ 4 at baseline, the proportion of subjec ts with a 4 -point reduction in WI-NRS pruritus 
score at Weeks 4, 12, and 24 as compared to b aseline will be calculated by treatment group and 
analyzed using a Cochran- Mantel -Haenszel test stratified by study site  and baseline disease 
severity  (see Section 4.2.2, Secondary Endpoints ). 
7.3.2. Scalpdex  
The Scalpdex will be analyzed as change from Day 1  in total score  as assessed at  Weeks 4, 12, 
and 24 using an analysis of covariance with treatment, baseline score, and the stratification factors as independent variables.  
7.4. Efficacy Endpoints 
7.4.1. Achievement of IGA ‘Completely Clear’ or ‘Almost Clear’  
The subject incidence of an IGA Assessment will be tabulated for each assessment.   
7.4.2. Achievement of IGA ‘Completely Clear’ or ‘Almost Clear’ plus a 2 -grade 
Improvement from Baseline  
The subject incidence of I GA of ‘ Completely Clear’ or ‘Almost Clear’ plus a 2 -grade 
improvement from Baseline will be tabulated for each assessment  
7.4.3. Achievement of a 2 -grade improvement in IGA from Baseline  
The subject incidence of a 2 -grade improvement in IGA from Baseline will be tabulated for each 
assessment.  
7.4.4. Duration of IGA Success 
Duration of IGA Success will be analyzed with the Kaplan -Meier method.    The rate of subjects 
remaining in IGA Success over time will be summarized descriptively.  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 58 of 73  7.4.5. Treatment -free Interval  
The time to re -starting IP will be analyzed with the Kaplan -Meier method.  The rate of subjects 
remaining off treatment over time will be summarized descriptively.  
7.4.6. Pharmacokinetic Analysis  
For Cohort 2 adolescent subjects, blood samples for the determination of roflumilast and its 
N-oxide metabolite will be collected as delineated in the Schedule of Visits and Assessments 
(Section 1.3 ). Plasma drug concentrations at Week 4 will be summarized using descriptive 
statistics. 
8. STUDY ADMINISTRATION 
8.1. Ethics  
8.1.1. Ethics  Review Board  
Before enrollment of subjects into the study, the current protocol, ICF , and any accompanying 
material to be provided to the subjects will be reviewed and approved by an appropriate IRB or IEC, as required by FDA (21 CFR § 56), Health Canada, and  ICH GCP  regulations.  A letter 
documenting the IRB or IEC approval must be received by the Sponsor before the initiation of the study at a  clinical site. Amendments to the protocol will be subject to the same requirements 
as the original protocol.   
The Investigator, Sponsor, or designee will submit a progress report at least once yearly to the IRB or IEC. However, the frequency of these reports will depend on IRB or IEC requirements. As soon as possible after completion or termination of the study, the Investigator will submit a 
final report to the IRB or IEC per the IRB or IEC requirements, and in compliance with FDA and 
Health Canada regulations and ICH GCP guidelines. 
The Investigator, the Sponsor, or designee shall promptly notify the IRB or IEC of any SAEs, 
SUSARs, or any other information that may affect the safe use of the IP  during the study, per the 
IRB or IEC local requirements, and in compliance with FDA and Hea lth Canada regulations and 
ICH GCP guidelines . 
8.1.2. Ethical Conduct of the Study  
This research will be carried out in accordance with the protocol,  the principles of the 
Tri-Council Policy Statement (TCPS), t he ethical principles set forth in the Declaration of 
Helsinki, and the ICH harmonized tripartite guideline regarding E6 (R2), December 2016. 
8.1.3. Subject Information and Consent  
The Investigator is responsible for obtaining written informed consent from each individual 
participating in this study and/or parent(s)/legal guardians, after adequate explanation 
(in non- technical terms) of the purpose of the study, the procedures to be carried out and the 
potential hazards before undertaking any study-related procedures. Subject and/or parent(s)/legal 
guardian(s) must provide their written informed consent prior to enrollment in a clinical trial and 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 59 of 73  before any protocol -specific procedures are  performed. The Investigator must use the most 
current approved consent form for documenting written informed consent. Subjects and/or 
parent(s)/legal guardian(s) will be assured that they may withdraw from the study at any time 
without jeopardizing their medical care. Each informed consent will be read, appropriately signed  and dated by the subject and/or parent(s)/legal guardian(s), the I nvestigator conducting 
the consent discussion, and by an impartial witness if required by local requirements.   
Adolesc ents will provide written assent  and their parent(s) or legal guardian(s) will provide 
consent, as required by local laws.  
Subjects and/or parent(s)/legal guardian(s) will be given a signed copy of their Consent/Assent . 
8.2. Study Completion and Termination  
8.2.1. Study Completion  
The study is considered completed with the last visit of the last subject participating in the study. 
The final data from the investigational site will be sent to the Sponsor (or designee) after 
completion of the final subject visit at that site, in the time frame specified in the Clinical Trial Agreement . 
8.2.2. Study Termination  
The Sponsor reserves the right to close the investigational site or terminate the study at any time for any reason at the sole discretion of the Sponsor. Investigational sites will be closed upon study completion. An investigational site is considered closed when all required documents and 
study supplies have been collected and a site closure visit has been performed. The I nvestigator 
may initiate site closure  at any time, provided there is reasonable cause and sufficient notice is 
given in advance of the intended termination. 
Reasons for the early closure of an investigational site by the Sponsor or I nvestigator may 
include but are not limited to:  
• Failure of the Investigator to comply with the protocol, the Sponsor’s procedures, or 
GCP guidelines. 
• Inadequate recruitment of subjects by the I nvestigator.  
• Discontinuation of further IP  development 
8.3. Study Monitoring  
Prior to the initiation of the clinical investigation, Sponsor representatives or designees will visit 
the clinical site where the investigation is to be conducted.  Sponsor representatives or designees 
shall ensure that the Investigator understands the investigational status of the investigational 
product, all requirements of the investigation to be undertaken, and all of his/her responsibilities 
as an Investigator.  Sponsor representatives or designees will also visit the clinical site at 
appropriate intervals as required to ensure compliance with the protocol and to verify the 
accuracy and completeness of data reported on the CRFs.  The Study Director or designees shall be available for consultation with the Investigator and serve as liaisons between the clinical site 
and the Sponsor. 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 60 of 73  The Sponsor or authorized designees may inspect  all documents and records required to be 
maintained by the Investigator, including but not limited to medical records (office, clinic, 
or hospital) and investigational product dispensation logs for the subjects in this clinical 
investigation.  The Investigator must permit access to such records.  The Investigator must obtain, as part of informed consent, permission for an authorized representative of the Sponsor, 
or regulatory authorities, to review, in confidence, any records identifying subjects.  
8.4. Data Quality Assurance 
In order to ensure the collection of accurate, consistent, complete, and reliable data during this clinical investigation, Sponsor representatives or designees may conduct audits of participating 
sites at appropri ate intervals throughout the study.  The results of these periodic site audits may 
be subject to review by independent auditors at completion of the clinical investigation.   
The Clinical Study Report will be audited by the Premier  Research’s Quality Assur ance (QA)  
department and the QA audit certificate will be included in the study report. 
All clinical data will undergo a 100% quality control check prior to clinical database lock. Edit 
checks are then performed for appropriate databases as a validation routine to check for missing 
data, data inconsistencies, data ranges etc. Corrections are made prior to database lock.  
8.5. Data Handling and Record Keeping 
During the clinical study, the Investigator will maintain adequate records, including medical records, records detailing the progress of the study for each subject, laboratory reports, signed informed consent forms, investigational product disposition records, correspondence with the 
IRB and Study Monitor/Sponsor, AE reports, and information regarding subject discontinuation 
and completion of the clinical investigation. 
All required study data will be recorded on eCRFs .  Any change of data will be recorded on the 
audit trail and a reason for the change will be entered.  
The P rincipal Investigator must retain all documentation relating to the study for a period of at 
least 2  years after the last marketing application approval or, if not approved, 2 years following 
the discontinuance of the test article for investigation.  If this requirement differs from any local 
regulations, the local regulations will take precedence unless the local retention policy is less than 2 years.   
8.6. Protocol Amendments and Deviations  
No change or amendment to this protocol may be made by the Investigator or Sponsor after th e 
protocol has been agreed to and signed by all parties unless such change(s) or amendment(s) has 
(have) been agreed upon by the Investigator and Sponsor.  Any change agreed upon will be 
recorded in writing, and the written amendment will be signed by the I nvestigator and Sponsor .  
Institutional review board approval is required prior to the implementation of an amendment, 
unless overriding safety reasons warrant immediate action, in which case the IRB(s) will be 
promptly notified. 
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 61 of 73  No deviation from the protocol will be made except to protect the life or physical well-being of a 
subject in an emergency.  Except in such emer gencies, prior approval of the Sponsor, and the 
IRB, is required before deviations from the planned protocol.  All protocol deviations that occur during the study will be documented and reported to Sponsor and to the IRB(s) , if applicable, 
according to regulations.  Further details about the documentation, evaluation, and follow-up of 
protocol deviations are detailed in this study’s clini cal monitoring plan.  
No waivers to inclusion/exclusion criteria will be granted; subjects need to meet all criteria, 
exactly as specified, to be enrolled.  Additionally, prospective deviations from the protocol or 
investigational plan are not permitted except to protect the life or physical well -being of a subject 
in an emergency.  Deviations that occur unintentionally or are the result of action by the subject 
must be documente d and reported to the IRB(s), if applicable, according to regulations.  Further 
details about the documentation, evaluation, and follow-up of protocol deviations are detailed in this study’s clinical monitoring plan.  
8.7. Confidentiality and Privacy 
The I nvestigator must assure that subjects’ anonymity will be strictly maintained and that their 
identities are protected from unauthorized parties. Only an identification code and any other unique identifier(s) as allowed by local law (such as date of birth) will be recorded on any form 
or biological sample submitted to the Sponsor.  
The Inves tigator agrees that all information received from Arcutis Inc., including but not limited 
to the IB, this protocol, CRF/eCRF, the IP, and any other study information, remain the sole and 
exclusive property of Arcutis Inc. during the conduct of the study and thereafter. This 
information is not to be disclosed to any third party (except employees or agents directly involved in the conduct of the study or as required by law) without prior written consent from 
Arcutis Inc. The Investigator further agrees to tak e all reasonable precautions to prevent the 
disclosure by any employee or agent of the study site to any third party or otherwise into the 
public domain. 
8.8. Conflict of Interest 
All study investigators will provide documentation of their financial interest or arrangements with Arcutis Biotherapeutics Inc., or proprietary interests in the IP  under study. This 
documentation must be provided prior to the I nvestigator’s participation in th e study. All 
investigators with reported conflict of interest will be required to have such conflicts managed in a way that is appropriate to their participation in the design and conduct of this study. 
8.9. Report Format 
According to the ICH Harmonized Triparti te Guideline (Organization of the Common Technical 
Document for the Registration of Pharmaceuticals for Human Use M4 and the ICH  M2 Expert 
Working Group), the final report will be written according to the ICH  E3 Guideline (Structure 
and Content of Clinical Study Reports).  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 62 of 73  8.10. Publication Policy 
The Sponsor is supportive of publishing clinical trial findings.  Any form of publication that is 
derived from this study must be submitted to Arcutis  Biotherapeutics , Inc. for review and 
approval. The process of coordi nating publication efforts is detailed in the Clinical Trial 
Agreement.  
  
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 63 of 73  9. REFERENCES  
Berger  RS, Bowman JP. A reappraisal of the 21- day Cumulative Irritation Test in man.  
J. Toxicol Ot & Ocular Toxicol . 1982:1(2);109-115. 
Bethke TD, Lahu G. High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor 
roflumilast.  Int. J Clin Pharmacol Ther . 2011;49:51-57. 
Borda LJ, Wikramanayake TC. Seborrheic Dermatitis and Dandruff: A Comprehensive Review. J Clin Investigat Dermatol. 2015;3(2):10.  
Cohen SR, Gordon SC, Lam  AH, et al.  Recalcitrant Seborrheic Dermatitis Successfully Treated 
with Apremilast. Journal of Cutaneous Medicine and Surgery . 2020;24(1):90-91.  
DALIRESP (roflumilast) tablets [package insert]. AstraZeneca Pharmaceuticals LP, Wilmington, DE USA, 2017. 
DAXAS (roflumilast) film-coated tablets [product monograph]. AstraZeneca Canada, Inc., 
Mississauga, Ontario Canada; 2017. 
Dessiniot  C, Katsambas A. Seborrheic dermatitis: Etiology, risk factors, and treatments: 
Facts and controversies. Clinics in Dermatology . 2013;31:343-351.  
Hatzelmann A, Morcillo EJ, Lungarella G, et al. The preclinical pharmacology of roflumilast – a 
selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary 
disease. Pulm Pharmacol Ther . 2010;23:235–256. 
Investigator’s Bro chure, Edition 4.0, 22 January 20 21 
Kimball AB, Naegeli AN, Edson- Heredia E, et  al. Psychometric properties of the Itch Numeric 
Rating Scale in patients with moderate -to-severe plaque psoriasis. Br. J. Dermatol. 
2016;175(1):157-162. doi:10.1111/bjd.1446. 
Liu D, Chow P, Strawn S, et al. Chronic Nasolabial Fold Seborrheic Dermatitis Successfully 
Controlled with Crisaborole. Journal of Drugs in Dermatology . 2018;17(5):577-578. 
Michalski JM, Golden G, Ikari J , et al . PDE4: A Novel Target in the Treatment of Chronic 
Obstructive Pulmonary Disease. Clinical Pharmacology & Therapeutics.  2012;91:134-142. 
Naegeli AN, Flood E, Tucker J, et al . The Worst Itch Numeric Rating Scale for patients with 
moderate to severe plaque psoriasis or psoriatic arthritis.  Int J Dermatol . 2015;54(6):715-22. 
Wedzicha JA, Calverley PMA, Klaus FR.  Roflumilast: a review of its use in the treatment of COPD.  International Journal of Chronic Obstructive Pulmonary Disease . 2016;11:81-90. 
Yosipovitch G, et al. Peak Pruritis Numerical Rating Scale: psychometric validation and 
responder definition for assessing itch in moderate -to-severe atopic dermat itis. Br J Dermatol .  
2019;181(4):761-769. doi:10.1111/bjd.17744.     
Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 64 of 73  10. APPENDICES  
APPENDIX 1. PATIENT HEALTH QUESTIONNAIRE D EPRESSION 
SCALE (PHQ- 8) 
 
  

Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 65 of 73  APPENDIX 2. PATIENT HEALTH QUESTIONNAIRE D EPRESSION 
SCALE (MODIFIED PHQ- A) 
 
  

Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 66 of 73  APPENDIX 3. COLUMBIA -SUICIDE  SEVERITY RATING SCALE 
(C-SSRS) BASELINE/SCREENING VERSION  
 

Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 67 of 73   
 

Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 68 of 73   
  

Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 69 of 73  APPENDIX 4. COLUMBIA -SUICIDE SEVERITY RATING SCALE 
(C-SSRS) SINCE LAST VISIT VERSION  
 

Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 70 of 73   
 
 

Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 71 of 73   
  

Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 72 of 73  APPENDIX 5. SCALPDEX  
 
  

Protocol ARQ-154-214 Arcutis  Biotherapeutics, Inc.  
Amendment 2 
 
04 November 2021 Confidential Page 73 of 73  APPENDIX 6. CHILDREN’S DEPRESSION INVENTORY 2 
(PARENT  REPORT)  
 
 
 
 
 
